Optimization of sequential administration of bevacizumab plus cytotoxics in non-small cell lung cancer by combining in vivo experiments and mathematical modeling

Sébastien Benzekry 1, 2
1 MONC - Modélisation Mathématique pour l'Oncologie
IMB - Institut de Mathématiques de Bordeaux, Inria Bordeaux - Sud-Ouest, Institut Bergonié - CRLCC Bordeaux
Abstract : Concomitant administration of bevacizumab and pemetrexed-cisplatin is a common treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Vascular normalization following bevacizumab administration may transiently enhance drug delivery, suggesting improved efficacy with sequential administration. To investigate optimal scheduling, we conducted a study in NSCLC-bearing mice that combined mathematical modeling with experimental investigations. First, experiments demonstrated improved efficacy when using sequential vs. concomitant scheduling of bevacizumab and chemotherapy. Combining this data with a mathematical model of tumor growth under therapy accounting for the normalization effect, we predicted an optimal delay of 2.8 days between bevacizumab and chemotherapy. This prediction was confirmed experimentally, with reduced tumor growth of 38% as compared to concomitant scheduling, and prolonged survival (74 vs. 70 days). Alternate sequencing of 8 days failed in achieving a similar increase in efficacy, thus emphasizing the utility of modeling support to identify optimal scheduling. The model could also be a useful tool in the clinic to personally tailor regimen sequences.
Complete list of metadatas

Cited literature [5 references]  Display  Hide  Download

https://hal.inria.fr/hal-01969142
Contributor : Sebastien Benzekry <>
Submitted on : Friday, January 4, 2019 - 11:04:17 AM
Last modification on : Thursday, May 9, 2019 - 1:40:17 PM
Long-term archiving on : Friday, April 5, 2019 - 12:51:01 PM

File

07_marseille_bevalung.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : hal-01969142, version 1

Citation

Sébastien Benzekry. Optimization of sequential administration of bevacizumab plus cytotoxics in non-small cell lung cancer by combining in vivo experiments and mathematical modeling. Mathematical perspectives in the biology and therapeutics of cancer, Jul 2018, Marseille, France. ⟨hal-01969142⟩

Share

Metrics

Record views

240

Files downloads

228